Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901115 | 1.00 | MAPK1 (0.54) | MAPK1ARCA1CA2CA9 | |
| SCHEMBL14901116 | 1.00 | MAPK1 (0.54) | MAPK1ARCA1CA2CA9 | |
| SCHEMBL1982314 | 0.84 | MAPK1 (0.65) | MAPK1ALDH1A1TSHRKDM4ETDP1 | |
| SCHEMBL7803008 | 0.81 | MAPK1 (0.50) | MAPK1ALDH1A1KDM4ETDP1 | |
| SCHEMBL9309371 | 0.79 | MAPK1 (0.59) | MAPK1ALDH1A1KDM4ETDP1 | |
| SCHEMBL18974154 | 0.78 | MAPK1 (0.52) | MAPK1ALDH1A1KDM4ETDP1 | |
| SCHEMBL8083397 | 0.77 | MAPK1 (0.56) | MAPK1ARALDH1A1TSHRKDM4E | |
| SCHEMBL12083370 | 0.77 | MAPK1 (0.56) | MAPK1ARALDH1A1TSHRKDM4E | |
| SCHEMBL14901102 | 0.77 | MAPK1 (0.56) | MAPK1ALDH1A1TSHRKDM4ETDP1 | |
| SCHEMBL2609782 | 0.77 | MAPK1 (0.56) | MAPK1ALDH1A1TSHRKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521707-B1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-06-14 | — | — | EP | disclosed |
| US-9388112-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-20130131167-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-23 | — | — | US | disclosed |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
| US-20070015943-A1 | Method of preparation of optically active alcohols | POSTECH FOUNDATION (KR) | 2007-01-18 | — | — | US | disclosed |
| WO-2005009935-A1 | METHOD OF PREPARATION OF OPTICALLY ACTIVE ALCOHOLS | POSTECH FOUNDATION (KR) | 2005-02-03 | — | — | WO | disclosed |
| EP-0060904-A1 | A process for making vicinal epoxides and alkyl halides or alkylene dihalides from carbonate esters | THE DOW CHEMICAL COMPANY (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4349482-A | Process for making vicinal epoxides and dihalides | THE DOW CHEMICAL CO. (US) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | SHBG, KLK3, HSD17B11 | MAPK1 3831/4885AR 4/4885CA1 4100/4885 |
| US-20130131167-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | CYP19A1, AR, SHBG | MAPK1 859/4885AR 2/4885CA1 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.